Brean Murray Carret & Co. Maintains a 'Buy' on Medivation (MDVN); Zytiga Data Better Than Expected

Brean Murray Carret & Co. maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $105.00.

Analyst, Jonathan Ashoff, said, "Johnson & Johnson's (NYSE: JNJ) Zytiga in the pre chemo setting demostrated robust PFS and OS results overall regardless of the patient subgroup analyzed, and had favorable safety profile. The results are beyond anything shown in the provenge trials, and as with the post chemo Zytiga results, we believe that Medivation's enzalutamide will outperform even the Zytiga pre chemo results presented this past weekend."

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $82.68 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
• GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
• UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)